Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry
Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)
Ho PJ, Moore E, Wellard C, Quach H, Blacklock H, Harrrison SJ, MacDonald EJ, McQuilten ZK, Wood EM, Mollee P, Spencer A. Br J Haematol. 2024 Jul 4. doi: 10.1111/bjh.19624.
Variation in immunoglobulin use and impact on survival in myeloma
Chai, KL, Wellard C, LTP T, Aoki N, Moore EM, Augustson BM, Bapat A, Blacklock H, Chng WJ, Cooke R, Forsyth CJ, Goh YT, Hamad N, Harrison SJ, Ho PJ, Hocking J, Kerridge I, Kim JS, Kim KH, King T, McCaughan GJ, Mollee P, Morrissey CO, Murphy N, Quach H, Tan XN, Tso ACY, Wong KSQ, Yoon SS, Spencer A, Wood EM, McQuilten ZK. EJHaem. 2024 May;1-8 doi: 10.1002/jha2.938
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry
Lim SL, Wellard C, Moore E, Harrison SJ, Hang Q, Ho J, Rajagopal R, Spencer A. Intern Med J. 2023 Dec 27. doi: 10.1111/imj.16277..
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
Lim KJ, Wellard C, Talaulikar D, Tan JL, Loh J, Puvanakumar P, Kuzich JA, Ho M, Murphy M, Zeglinas N, Low MS, Routledge D, Lim AB, Gibbs, SD, Quach H, Morgan S, Moore E and Ninkovic S. EJHaem. 2023 Jul;4(3): e639-e646. doi:10.1002/jha2.742
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population
Tan JLC, Wellard C, Moore EM, Mollee P, Rajagopal R, Quach H, Harrison SJ, McDonald E, Ho PJ, Prince HM, Augustson BM, Campbell P, McQuilten ZK, Wood EM, Spencer A, and Myeloma and Related Diseases Registry Investigators. Br J Haematol. 2023 Jan;200(2):e17-e21. doi:10.1111/bjh.18536.
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison SJ, Ho PJ, King T, Quach H, Mollee P, B Rosengarten, Walker P, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. https://doi.org/10.1111/bjh.18324. Published:June 9, 2022.
Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
Moore EM, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, George A, Baker B, Chan H, McQuilten ZK, Wood EM, Spencer A, MRDR investigators. Clin Lymphoma Myeloma Leuk. 2022 Apr 8: S2152-2650(22)00118-5. doi: 10.1016/j.clml.2022.04.004. Published:April 8, 2022.
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Eur J Haematol. Published:June 15, 2021.
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealad myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bone Marrow Transplant. Published: May 19, 2021.
The Myeloma Landscape in Australia and New Zealand (ANZ): The First Eight Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K, Wellard C, Moore EM, McQuilten Z, Augustson B, Blacklock H, Harrison SH, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood EM, Spencer A, on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry. Clin Lymphoma Myeloma Leuk. Published:January 29, 2021.
Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.
Moore EM, King TA, Wood EM, Ruseckaite R, Klarica D, Spencer A, Ho PJ, Quach H, Prince HM, McQuilten ZK. Am J Hematol. 2020 Jul;95(7):e178-181.
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424.
Myeloma in the Real World: What Is Really Happening?
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.
Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.
Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, Spencer A. BMC Med Res Methodol. 2016 Nov 9;16(1):151.